[Effects of 89SrCl2 treatment on CD4+ CD25+ regulatory T cells and its Foxp3 mRNA expression in cancer patients with bone metastases].
To study the influence of 89SrCl2 on CD4+ CD25+ regulatory T cells and its Foxp3 mRNA expression in cancer patients with bone metastases. Peripheral blood samples were collected from 57 patients with bone metastases cancer and 25 healthy controls, the amount of CD4+ CD25+ regulatory T cells in peripheral blood was determined by flow cytometry, the expression level of Foxp3 mRNA in these regulatory T cells was detected by RT-PCR. The percentage of CD4+ CD25+ regulatory T cells in CD4+ cells was (11.3 +/- 5.5) % in the patients with bone metastases, which was significantly more than that (5.6 +/- 1.5)% in healthy control (P < 0.01). After the treatment of 89SrCl2, it was decreased to (10.4 +/- 5.2)%, and the decrease was statistically significant (P < 0.05). The expression level of Foxp3 mRNA was decreased significantly from 0.348 +/- 0.028 to 0.296 +/- 0.029 by the treatment of 89SrCl2 (P < 0.05). In addition, the amount of CD4+ CD25+ T cells in the patients obtaining 89SrCl2 therapeutic effects was (9.3 +/- 4.2) %, which was lower than that in those patients without effects (12.9 +/- 5.3)% (P < 0.01). The relative expression level of Foxp3 mRNA was 0.254 +/- 0.025 in the patients obtaining therapeutic effects, which was also significantly less than that (0.397 +/- 0.029) in those patients without any effects (P < 0.01). Foxp3 gene play a pivotal role in the regulation of CD4+ CD25+ T cells. The treatment of 89SrCl2 could decrease the amount of CD4+ CD25+ T cells and down-regulate Foxp3 mRNA expression of these cells in bone metastases cancer patients.